Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT -

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the first quarter ended March 31, 2024 on Thursday, May 2 after the close of trading.